The EMA’s human medicines advisory committee has recommended approval of Eli Lilly’s Baqsimi as the first needle-free treatment for severe low blood sugar levels (hypoglycaemia) in diabetics ...

Eli Lilly’s intranasal formulation of glucagon – called Baqsimi – is the first alternative to injectable glucagon for severe hypoglycaemia, which typically occurs when people with diabetes ...